All In Biotech

Investigational drug · Phase 2

rivogenlecleucel

Also called: BPX-501 T cells, BPX-501

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Leukemia, Acute Myeloid (AML), Child.

Phase 2

Last checked: Nov 19, 2026Latest source record: Jul 12, 2022 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

9

Any phase or sponsor naming "rivogenlecleucel"

First trial start

2013

Mar 2013

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "rivogenlecleucel", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Acute Lymphoblastic Leukemia
  • Myelodysplastic Syndromes
  • Leukemia, Acute Myeloid (AML), Child
  • Lymphoma, Non-Hodgkin
  • Primary Immune Deficiency Disorder
  • Osteopetrosis
  • Cytopenia
  • Hemoglobinopathy in Children
  • Anemia, Aplastic
  • Acute Myelogenous Leukemia

Approved drugs for the same conditions: Acute lymphoblastic leukemia · Lymphoma (non-Hodgkin) · Myelodysplastic syndromes · Anemia · Hematology and blood cancers · Rare and genetic disease

Largest trials

Live from ClinicalTrials.gov: studies naming "rivogenlecleucel" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 2 on PubMed

Also in development for Acute Lymphoblastic Leukemia

  • MK-1045CN-201Phase 36 trials

    Merck & Co. · Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, Follicular

  • RimiducidAP1903Phase 23 trials

    Bellicum Pharmaceuticals · Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Leukemia, Acute Myeloid (AML), Child

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.